Johannes Petzold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Johannes Petzold has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Maik Spreer
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Dresden, Technische Universität Dresden, Dresden, Deutschland
8 shared publications - Michael N. Smolka
Department of Psychiatry and Psychotherapy, Technische Universität Dresden
8 shared publications - Maximilian Pilhatsch
Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany
6 shared publications Maximilian Pilhatsch
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität Dresden
5 shared publications- Max Schallenberg
Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital Dresden, Carl Gustav Carus Faculty of Medicine Dresden, Dresden University of Technology, Dresden, Germany
4 shared publications Michael Bauer
Department of Psychiatry and Psychotherapy, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany
4 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Springer Nature in Der Nervenarzt
- Vol. 97 (6) , 600-602
Elektrokonvulsionstherapie bei jahrzehntelang therapieresistenter schizoaffektiver Störung: Remission und Wiedererlangung der Einwilligungsfähigkeit
- 7 September 2026
- Published by Springer Nature in Der Nervenarzt
- Vol. 97 (6) , 600-602
Open AccessElektrokonvulsionstherapie bei jahrzehntelang therapieresistenter schizoaffektiver Störung: Remission und Wiedererlangung der Einwilligungsfähigkeit
- 17 December 2025
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (02) , 88-96
Ergebnisse zu „Mama denk an mich“: Ein Versorgungsprogramm für methamphetaminabhängige Mütter und Väter
Zusammenfassung: Methamphetamin(MA)-Konsum hat ab etwa 2008 in einigen Regionen Deutschlands stark zugenommen, auch unter jungen Frauen im gebärfähigen Alter. Einerseits birgt MA-Konsum hohe Risiken für Mutter und Kind. Andererseits bieten Schwangerschaft und Elternschaft eine Chance, Betroffene in Therapien zu integrieren, die wegen unzureichender spezifischer Therapiemöglichkeiten jedoch häufig nicht genutzt wird. Vor diesem Hintergrund wurde 2016 am Universitätsklinikum Dresden das Programm „Mama denk an mich“ (MAMADAM) entwickelt – ein interdisziplinäres, niedrigschwelliges Therapieangebot für Schwangere, Mütter und Väter mit MA-bezogener Störung (MBS). Im vorliegenden Artikel werden bisherige Evaluationsergebnisse zum MAMADAM-Programm zusammengefasst, um Wirksamkeit, Umsetzbarkeit und versorgungspolitische Relevanz zu beurteilen, Schlussfolgerungen für die Weiterentwicklung des Programms zu ziehen und künftige Forschungs- und Implementierungsstrategien aufzuzeigen. Es werden zunächst die Konzeption und Bestandteile des MAMADAM-Programms beschrieben sowie auf die methodischen Ansätze der Programm-Evaluation eingegangen. Die bisherigen Auswertungen beruhen auf naturalistischen Verlaufsbeobachtungen der ersten Patientenkohorten. Diese werden systematisch zusammengestellt und vergleichend bewertet. Bislang nahmen über 150 Eltern mit MBS am MAMADAM-Programm teil, überwiegend junge Frauen (Durchschnittsalter ~29 Jahre) und in prekären Lebensverhältnissen. Mehr als die Hälfte befand sich erstmalig in suchtspezifischer Behandlung. Hauptkonsumsubstanz war in ~65% MA. Trotz überwiegend extrinsischer Motivation (ca. 70%) und erheblicher psychosozialer Belastungen verblieben rund zwei Drittel im Programm. Depressive Störungen und unbehandelte ADHS minderten die Erfolgswahrscheinlichkeit. MAMADAM zeigt, dass selbst hochbelastete MA-Konsumierende während Schwangerschaft und Elternschaft durch ein maßgeschneidertes ambulantes Angebot erreicht werden können. Die Zusammenarbeit mit Gynäkologie, Pädiatrie, Jugendamt und Suchthilfe ermöglicht frühzeitige Integration Betroffener und gewährleistet Kinderschutz parallel zur Suchtbehandlung. Als Erfolgskriterien lassen sich das niedrigschwellige, integrative Versorgungssetting sowie die Nutzung von Elternschaft als Motivationsfaktor identifizieren. Das Programm schließt eine Versorgungslücke und sollte sowohl regional ausgeweitet als auch strukturell in die Regelversorgung integriert werden.
- 17 December 2025
- Published by Georg Thieme Verlag KG in Suchttherapie
- Vol. 27 (02) , 88-96
Ergebnisse zu „Mama denk an mich“: Ein Versorgungsprogramm für methamphetaminabhängige Mütter und Väter
Zusammenfassung: Methamphetamin(MA)-Konsum hat ab etwa 2008 in einigen Regionen Deutschlands stark zugenommen, auch unter jungen Frauen im gebärfähigen Alter. Einerseits birgt MA-Konsum hohe Risiken für Mutter und Kind. Andererseits bieten Schwangerschaft und Elternschaft eine Chance, Betroffene in Therapien zu integrieren, die wegen unzureichender spezifischer Therapiemöglichkeiten jedoch häufig nicht genutzt wird. Vor diesem Hintergrund wurde 2016 am Universitätsklinikum Dresden das Programm „Mama denk an mich“ (MAMADAM) entwickelt – ein interdisziplinäres, niedrigschwelliges Therapieangebot für Schwangere, Mütter und Väter mit MA-bezogener Störung (MBS). Im vorliegenden Artikel werden bisherige Evaluationsergebnisse zum MAMADAM-Programm zusammengefasst, um Wirksamkeit, Umsetzbarkeit und versorgungspolitische Relevanz zu beurteilen, Schlussfolgerungen für die Weiterentwicklung des Programms zu ziehen und künftige Forschungs- und Implementierungsstrategien aufzuzeigen. Es werden zunächst die Konzeption und Bestandteile des MAMADAM-Programms beschrieben sowie auf die methodischen Ansätze der Programm-Evaluation eingegangen. Die bisherigen Auswertungen beruhen auf naturalistischen Verlaufsbeobachtungen der ersten Patientenkohorten. Diese werden systematisch zusammengestellt und vergleichend bewertet. Bislang nahmen über 150 Eltern mit MBS am MAMADAM-Programm teil, überwiegend junge Frauen (Durchschnittsalter ~29 Jahre) und in prekären Lebensverhältnissen. Mehr als die Hälfte befand sich erstmalig in suchtspezifischer Behandlung. Hauptkonsumsubstanz war in ~65% MA. Trotz überwiegend extrinsischer Motivation (ca. 70%) und erheblicher psychosozialer Belastungen verblieben rund zwei Drittel im Programm. Depressive Störungen und unbehandelte ADHS minderten die Erfolgswahrscheinlichkeit. MAMADAM zeigt, dass selbst hochbelastete MA-Konsumierende während Schwangerschaft und Elternschaft durch ein maßgeschneidertes ambulantes Angebot erreicht werden können. Die Zusammenarbeit mit Gynäkologie, Pädiatrie, Jugendamt und Suchthilfe ermöglicht frühzeitige Integration Betroffener und gewährleistet Kinderschutz parallel zur Suchtbehandlung. Als Erfolgskriterien lassen sich das niedrigschwellige, integrative Versorgungssetting sowie die Nutzung von Elternschaft als Motivationsfaktor identifizieren. Das Programm schließt eine Versorgungslücke und sollte sowohl regional ausgeweitet als auch strukturell in die Regelversorgung integriert werden.
- Open Access
- 25 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Sustained abstinence after a methamphetamine-specific treatment program for pregnant and parenting women
The treatment of methamphetamine use disorder (MUD) poses a significant challenge due to high rates of treatment discontinuation, substance use recurrence, and socioeconomic adversity. ‘Mummy, think of me’ (MAMADAM, an acronym from the German “Mama, denk an mich”), a treatment program specifically designed for pregnant women and young mothers with substance use disorders, has shown positive results regarding treatment efficacy and retention of child custody. This study aimed to evaluate the long-term sustainability of the MAMADAM intervention, which has not yet been examined. For this retrospective follow-up study, former patients with MUD who were pregnant and/or parenting women at the time of MAMADAM treatment were contacted by telephone. We analyzed whether self-reported abstinence after discharge from MAMADAM was associated with patient characteristics at admission to MAMADAM. Of the 114 eligible women, 39 participated in the follow-up interview, on average, 4.5 years after completing MAMADAM. Of these, 16 (41%) reported sustained abstinence from all addictive substances, excluding tobacco. At 12 and 18 months after discharge from MAMADAM, 9/39 (23%) and 11/39 (28%) women, respectively, reported at least one instance of substance use, including alcohol but excluding tobacco. Women who reported recurrences of substance use were significantly more likely to have more underage children, live apart from at least one minor, and consume methamphetamine for longer before MAMADAM than women with sustained abstinence. Cox regression, controlling for the duration of MAMADAM treatment, indicated that a longer history of methamphetamine use at admission to MAMADAM was associated with a shorter period of abstinence from all addictive substances (excluding tobacco) following discharge. The MAMADAM program is effective and sustainable in supporting long-term abstinence among pregnant and parenting women with MUD, indicating that pregnancy and parenthood can serve as turning points for promoting the necessary behavioral changes for recovery from addiction. Some women remain at elevated risk of relapse due to the vulnerabilities identified in this study. Future research should investigate whether stronger collaborations with government and community agencies can help these women maintain long-term abstinence.
- 25 September 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessSustained abstinence after a methamphetamine-specific treatment program for pregnant and parenting women
The treatment of methamphetamine use disorder (MUD) poses a significant challenge due to high rates of treatment discontinuation, substance use recurrence, and socioeconomic adversity. ‘Mummy, think of me’ (MAMADAM, an acronym from the German “Mama, denk an mich”), a treatment program specifically designed for pregnant women and young mothers with substance use disorders, has shown positive results regarding treatment efficacy and retention of child custody. This study aimed to evaluate the long-term sustainability of the MAMADAM intervention, which has not yet been examined. For this retrospective follow-up study, former patients with MUD who were pregnant and/or parenting women at the time of MAMADAM treatment were contacted by telephone. We analyzed whether self-reported abstinence after discharge from MAMADAM was associated with patient characteristics at admission to MAMADAM. Of the 114 eligible women, 39 participated in the follow-up interview, on average, 4.5 years after completing MAMADAM. Of these, 16 (41%) reported sustained abstinence from all addictive substances, excluding tobacco. At 12 and 18 months after discharge from MAMADAM, 9/39 (23%) and 11/39 (28%) women, respectively, reported at least one instance of substance use, including alcohol but excluding tobacco. Women who reported recurrences of substance use were significantly more likely to have more underage children, live apart from at least one minor, and consume methamphetamine for longer before MAMADAM than women with sustained abstinence. Cox regression, controlling for the duration of MAMADAM treatment, indicated that a longer history of methamphetamine use at admission to MAMADAM was associated with a shorter period of abstinence from all addictive substances (excluding tobacco) following discharge. The MAMADAM program is effective and sustainable in supporting long-term abstinence among pregnant and parenting women with MUD, indicating that pregnancy and parenthood can serve as turning points for promoting the necessary behavioral changes for recovery from addiction. Some women remain at elevated risk of relapse due to the vulnerabilities identified in this study. Future research should investigate whether stronger collaborations with government and community agencies can help these women maintain long-term abstinence.
- Open Access
- 5 August 2025
- Published by Springer Nature in Der Nervenarzt
- Vol. 96 (6) , 600-604
Impulsive suicide in methamphetamine intoxication and self-reported ADHD: a case report
- 5 August 2025
- Published by Springer Nature in Der Nervenarzt
- Vol. 96 (6) , 600-604
Open AccessImpulsive suicide in methamphetamine intoxication and self-reported ADHD: a case report
- Open Access
- 22 April 2025
- Published by Wiley in Addiction Biology
- Vol. 30 (4) , e70035
Effectiveness of Disulfiram as Adjunct to Addiction‐Focused Treatment for Persons With Severe Alcohol Use Disorder
The consumption of alcohol affects 400 million people worldwide, where it is responsible for 7% of deaths. Treatment success rates in this field remain limited. Only 15% of those who need treatment get it. Despite treatment, alcohol intake reoccurs in up to 90% of the cases. The use of disulfiram in preventing alcohol reoccurrence is attributed to its unique mechanism of action as an aversive agent, which causes the patient to experience unpleasant physical symptoms when they consume alcohol. The objective of this study is to confirm and illustrate the efficacy of disulfiram in combination with non‐pharmacological intervention for persons with severe AUD. Clinical data from 45 patients of an outpatient treatment programme, including the application of disulfiram (2011–2023) were analysed to assess abstinence rates, craving impact, and demographic factors. Moreover, our analyses aimed to identify predictors and moderators of continuous abstinence duration. The study cohort comprised patients with severe AUD and high rates of comorbidities, the majority of which were affective disorders. During treatment, 50% of patients remained abstinent for at least 1 year. No significant differences were identified in craving, sex or comorbidities compared with those who experienced a return to substance use after treatment initiation. Disulfiram underlined its efficacy and tolerability as an adjunct to addiction‐focused treatment in a typical clinical cohort of patients severely affected by AUD. Moreover, our analyses align with previous research indicating that disulfiram appears to allow patients with AUD to resist craving episodes, therefore avoiding impulsive reoccurrences of alcohol intake.
- 22 April 2025
- Published by Wiley in Addiction Biology
- Vol. 30 (4) , e70035
Open AccessEffectiveness of Disulfiram as Adjunct to Addiction‐Focused Treatment for Persons With Severe Alcohol Use Disorder
The consumption of alcohol affects 400 million people worldwide, where it is responsible for 7% of deaths. Treatment success rates in this field remain limited. Only 15% of those who need treatment get it. Despite treatment, alcohol intake reoccurs in up to 90% of the cases. The use of disulfiram in preventing alcohol reoccurrence is attributed to its unique mechanism of action as an aversive agent, which causes the patient to experience unpleasant physical symptoms when they consume alcohol. The objective of this study is to confirm and illustrate the efficacy of disulfiram in combination with non‐pharmacological intervention for persons with severe AUD. Clinical data from 45 patients of an outpatient treatment programme, including the application of disulfiram (2011–2023) were analysed to assess abstinence rates, craving impact, and demographic factors. Moreover, our analyses aimed to identify predictors and moderators of continuous abstinence duration. The study cohort comprised patients with severe AUD and high rates of comorbidities, the majority of which were affective disorders. During treatment, 50% of patients remained abstinent for at least 1 year. No significant differences were identified in craving, sex or comorbidities compared with those who experienced a return to substance use after treatment initiation. Disulfiram underlined its efficacy and tolerability as an adjunct to addiction‐focused treatment in a typical clinical cohort of patients severely affected by AUD. Moreover, our analyses align with previous research indicating that disulfiram appears to allow patients with AUD to resist craving episodes, therefore avoiding impulsive reoccurrences of alcohol intake.
- Open Access
- 19 April 2025
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 49 (6) , 1306-1320
Higher alcohol use is associated with subsequent increased risk seeking toward gains: A longitudinal cohort study in young men
Background: A higher propensity for impulsive and risky choices has often been reported in individuals with addiction, such as alcohol use disorder (AUD). Although domains of choice impulsivity, for example, temporal discounting, have been identified to predispose the development of hazardous alcohol use, research on altered decision making as a consequence of drinking is scarce. These may be particularly pronounced during periods of progressive brain development, such as young adulthood.Methods: This 3‐year prospective study investigated the effects of alcohol use on changes in four decision‐making domains in 18‐year‐old men (N = 130). We assessed temporal changes in discounting of delayed rewards, risk aversion for gains, risk seeking for losses, and loss aversion. By correlating three‐year cumulative alcohol consumption and total binge drinking frequency with respective change scores, we aimed to explore the influences of drinking on altered development in different impulsive choice tendencies.Results: From ages 18 to 21, choice impulsivity in our moderately drinking cohort decreased significantly with respect to temporal discounting and risk aversion for gains, while risk seeking for losses and loss aversion did not change significantly. Importantly, higher cumulative alcohol intake and more binge drinking occasions over 3 years were associated with slower increases in risk aversion for gains, that is, the general trend for lower choice impulsivity was diminished. Such relationships were not found for temporal discounting, risk seeking for losses, or loss aversion.Conclusions: Alcohol consumption in young adulthood is linked to stunted development of risk aversion for gains. Given that risk seeking for gains was previously identified as a risk factor for increasing alcohol intake, this relationship may reinforce a spiral of escalating consumption over time. The absence of similar findings in other decision‐making domains suggests that drinking behavior and modifying factors interact differently across domains, rather than universally enhancing impulsive choice behavior.
- 19 April 2025
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 49 (6) , 1306-1320
Open AccessHigher alcohol use is associated with subsequent increased risk seeking toward gains: A longitudinal cohort study in young men
Background: A higher propensity for impulsive and risky choices has often been reported in individuals with addiction, such as alcohol use disorder (AUD). Although domains of choice impulsivity, for example, temporal discounting, have been identified to predispose the development of hazardous alcohol use, research on altered decision making as a consequence of drinking is scarce. These may be particularly pronounced during periods of progressive brain development, such as young adulthood.Methods: This 3‐year prospective study investigated the effects of alcohol use on changes in four decision‐making domains in 18‐year‐old men (N = 130). We assessed temporal changes in discounting of delayed rewards, risk aversion for gains, risk seeking for losses, and loss aversion. By correlating three‐year cumulative alcohol consumption and total binge drinking frequency with respective change scores, we aimed to explore the influences of drinking on altered development in different impulsive choice tendencies.Results: From ages 18 to 21, choice impulsivity in our moderately drinking cohort decreased significantly with respect to temporal discounting and risk aversion for gains, while risk seeking for losses and loss aversion did not change significantly. Importantly, higher cumulative alcohol intake and more binge drinking occasions over 3 years were associated with slower increases in risk aversion for gains, that is, the general trend for lower choice impulsivity was diminished. Such relationships were not found for temporal discounting, risk seeking for losses, or loss aversion.Conclusions: Alcohol consumption in young adulthood is linked to stunted development of risk aversion for gains. Given that risk seeking for gains was previously identified as a risk factor for increasing alcohol intake, this relationship may reinforce a spiral of escalating consumption over time. The absence of similar findings in other decision‐making domains suggests that drinking behavior and modifying factors interact differently across domains, rather than universally enhancing impulsive choice behavior.
- Open Access
- 17 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Impact of Covid-19 pandemic on trajectories of patients with severe alcohol use disorder treated with disulfiram
The manifestations and progression of alcohol use disorder (AUD) are influenced by a number of contextual factors, with the current coronavirus pandemic being a significant example. This pandemic has profoundly impacted nearly all aspects of human life and has, therefore, strongly influenced patients suffering from AUD. In some cases, the pandemic has led to a reduction in severity, while in others, it has had the opposite effect. In our own work we have been investigating the negative impact of the pandemic on 45 patients with AUD who were undergoing outpatient treatment, including supervised use of disulfiram (Antabuse), in a close-knit program. A linear trend analysis demonstrated significant alterations in the retention rate over a 3-year period, encompassing the pre-pandemic, pandemic, and post-pandemic periods. During the pandemic the number of treatment cancellations virtually increased. Following the pandemic, a tendency towards the normalization of patient numbers was observed. Our data indicate a high level of vulnerability among patients with severe AUD and highlight a need for the development of alternative, possibly telemedical, treatment methods.
- 17 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-7
Open AccessImpact of Covid-19 pandemic on trajectories of patients with severe alcohol use disorder treated with disulfiram
The manifestations and progression of alcohol use disorder (AUD) are influenced by a number of contextual factors, with the current coronavirus pandemic being a significant example. This pandemic has profoundly impacted nearly all aspects of human life and has, therefore, strongly influenced patients suffering from AUD. In some cases, the pandemic has led to a reduction in severity, while in others, it has had the opposite effect. In our own work we have been investigating the negative impact of the pandemic on 45 patients with AUD who were undergoing outpatient treatment, including supervised use of disulfiram (Antabuse), in a close-knit program. A linear trend analysis demonstrated significant alterations in the retention rate over a 3-year period, encompassing the pre-pandemic, pandemic, and post-pandemic periods. During the pandemic the number of treatment cancellations virtually increased. Following the pandemic, a tendency towards the normalization of patient numbers was observed. Our data indicate a high level of vulnerability among patients with severe AUD and highlight a need for the development of alternative, possibly telemedical, treatment methods.
- Open Access
- 4 December 2024
- Published by Springer Nature in Journal of Adult Development
- Vol. 32 (4) , 393-405
Value-Based Decision-Making and Its Relation to Cognition and Processing Noise in Young and Older Adults
In all phases of life, people face decisions with important consequences. Weighing options involves using cognitive resources to assess valence, delay, and risk to achieve a desired outcome. Value-based decision-making changes over the lifespan, but studies disagree on the extent, domains, and mechanisms of this change. We assessed delay discounting, risk aversion for probabilistic gains, risk seeking for probabilistic losses, loss aversion as well as cognitive abilities, and processing noise in 86 young (25–38 years) and 93 older (63–76 years) adults. We tested whether decision-making differed between age groups and whether differences were mediated by cognitive abilities or processing noise as measured by reaction time variability and decision inconsistency. Older adults showed steeper delay discounting (p = .003) and trended towards more risk aversion for gains (p = .071). Age groups did not differ in risk seeking for losses or loss aversion. Lower decision consistency and better spatial working memory mediated older adults’ steeper delay discounting. The relationship between delay discounting and age persisted when controlling for both mediators, suggesting robust age differences in delay discounting. This persistent age difference implies mechanisms beyond noise or cognitive parameters, such as changing life circumstances or limited future perspective.
- 4 December 2024
- Published by Springer Nature in Journal of Adult Development
- Vol. 32 (4) , 393-405
Open AccessValue-Based Decision-Making and Its Relation to Cognition and Processing Noise in Young and Older Adults
In all phases of life, people face decisions with important consequences. Weighing options involves using cognitive resources to assess valence, delay, and risk to achieve a desired outcome. Value-based decision-making changes over the lifespan, but studies disagree on the extent, domains, and mechanisms of this change. We assessed delay discounting, risk aversion for probabilistic gains, risk seeking for probabilistic losses, loss aversion as well as cognitive abilities, and processing noise in 86 young (25–38 years) and 93 older (63–76 years) adults. We tested whether decision-making differed between age groups and whether differences were mediated by cognitive abilities or processing noise as measured by reaction time variability and decision inconsistency. Older adults showed steeper delay discounting (p = .003) and trended towards more risk aversion for gains (p = .071). Age groups did not differ in risk seeking for losses or loss aversion. Lower decision consistency and better spatial working memory mediated older adults’ steeper delay discounting. The relationship between delay discounting and age persisted when controlling for both mediators, suggesting robust age differences in delay discounting. This persistent age difference implies mechanisms beyond noise or cognitive parameters, such as changing life circumstances or limited future perspective.
- Open Access
- 2 December 2024
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 19 (1) , 1-5
Regaining control over alcohol intake but not abstinence on disulfiram medication, as a harm reduction approach: 2 case reports
Background: Alcohol use disorder (AUD) poses severe health risks, yet many affected individuals opt out of complete abstinence. Therefore, harm reduction strategies have become more prominent in treatment guidelines for AUD. Our two case reports illustrate how disulfiram, initially intended to enforce abstinence, was repurposed to support reduced drinking. Case Presentations: A 41-year-old patient with a history of severe AUD successfully reduced his alcohol consumption to a low-risk level by leveraging the effects of the disulfiram-alcohol aversive reaction. Another patient, a 63-year-old woman with long histories of AUD and major depressive disorder, experienced fewer depressive episodes and hospitalizations with disulfiram therapy despite periodically intentional discontinuation of medication. Conclusion: Individualized treatment strategies are critical in optimizing outcomes for patients with AUD. Continuous disulfiram therapy, despite its limitations in directly reducing alcohol intake, might offer a new avenue for harm reduction in exceptional cases even if alcohol consumption continues. The cases suggest that maintaining therapy, aiming at reduced drinking, can enhance the therapeutic alliance and help manage comorbid conditions. Regular medical monitoring is essential for safety and efficacy, warranting further study of possible long-term consequences and psychotropic effects of elevated acetaldehyde levels related to the disulfiram-alcohol interaction.
- 2 December 2024
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 19 (1) , 1-5
Open AccessRegaining control over alcohol intake but not abstinence on disulfiram medication, as a harm reduction approach: 2 case reports
Background: Alcohol use disorder (AUD) poses severe health risks, yet many affected individuals opt out of complete abstinence. Therefore, harm reduction strategies have become more prominent in treatment guidelines for AUD. Our two case reports illustrate how disulfiram, initially intended to enforce abstinence, was repurposed to support reduced drinking. Case Presentations: A 41-year-old patient with a history of severe AUD successfully reduced his alcohol consumption to a low-risk level by leveraging the effects of the disulfiram-alcohol aversive reaction. Another patient, a 63-year-old woman with long histories of AUD and major depressive disorder, experienced fewer depressive episodes and hospitalizations with disulfiram therapy despite periodically intentional discontinuation of medication. Conclusion: Individualized treatment strategies are critical in optimizing outcomes for patients with AUD. Continuous disulfiram therapy, despite its limitations in directly reducing alcohol intake, might offer a new avenue for harm reduction in exceptional cases even if alcohol consumption continues. The cases suggest that maintaining therapy, aiming at reduced drinking, can enhance the therapeutic alliance and help manage comorbid conditions. Regular medical monitoring is essential for safety and efficacy, warranting further study of possible long-term consequences and psychotropic effects of elevated acetaldehyde levels related to the disulfiram-alcohol interaction.
- Open Access
- 23 November 2023
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 37 (12) , 1218-1226
Value-based decision-making predicts alcohol use and related problems in young men
Background: Alcohol consumption is a leading cause of morbidity and mortality worldwide, disproportionately affecting young men. Heavy episodic drinking is particularly prevalent among men, with this behavior peaking between the ages of 20 and 24. Aims: We sought to identify dimensions of decision-making in men that would predict the development of hazardous alcohol use through emerging adulthood. Methods: This prospective observational study profiled value-based decision-making in 198 healthy men at age 18 and assessed their alcohol involvement annually until age 24. Latent growth curve modeling estimated individual variability in trajectories of alcohol involvement and regressed this variability on five choice dimensions. Results: Low loss aversion predicted sustained heavy episodic drinking from age 18 to 24. Both high delay discounting and risk-seeking for gains independently predicted a considerably higher cumulative alcohol use during these 6 years, with high delay discounting indicating escalating consumption from age 21. Risk-seeking for gains additionally predicted meeting more criteria for Alcohol Use Disorder in these 6 years. Risk-seeking for losses was not significantly related to alcohol outcomes. Choice preferences were largely independent of each other but were correlated with choice consistency, with low consistency predicting heavy episodic drinking from age 18 to 24 beyond these associations. Conclusions: The predictive effects collectively suggest that overvaluing immediate and probabilistic incentives, rather than underestimating harm, drives hazardous drinking in young men. The differential relations of choice preferences and consistency to alcohol involvement through emerging adulthood provide distinct cognitive-behavioral patterns that warrant consideration in the development of harm reduction interventions.
- 23 November 2023
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 37 (12) , 1218-1226
Open AccessValue-based decision-making predicts alcohol use and related problems in young men
Background: Alcohol consumption is a leading cause of morbidity and mortality worldwide, disproportionately affecting young men. Heavy episodic drinking is particularly prevalent among men, with this behavior peaking between the ages of 20 and 24. Aims: We sought to identify dimensions of decision-making in men that would predict the development of hazardous alcohol use through emerging adulthood. Methods: This prospective observational study profiled value-based decision-making in 198 healthy men at age 18 and assessed their alcohol involvement annually until age 24. Latent growth curve modeling estimated individual variability in trajectories of alcohol involvement and regressed this variability on five choice dimensions. Results: Low loss aversion predicted sustained heavy episodic drinking from age 18 to 24. Both high delay discounting and risk-seeking for gains independently predicted a considerably higher cumulative alcohol use during these 6 years, with high delay discounting indicating escalating consumption from age 21. Risk-seeking for gains additionally predicted meeting more criteria for Alcohol Use Disorder in these 6 years. Risk-seeking for losses was not significantly related to alcohol outcomes. Choice preferences were largely independent of each other but were correlated with choice consistency, with low consistency predicting heavy episodic drinking from age 18 to 24 beyond these associations. Conclusions: The predictive effects collectively suggest that overvaluing immediate and probabilistic incentives, rather than underestimating harm, drives hazardous drinking in young men. The differential relations of choice preferences and consistency to alcohol involvement through emerging adulthood provide distinct cognitive-behavioral patterns that warrant consideration in the development of harm reduction interventions.